thiosemicarbazide has been researched along with Toxoplasmosis* in 2 studies
2 other study(ies) available for thiosemicarbazide and Toxoplasmosis
| Article | Year |
|---|---|
4-Arylthiosemicarbazide derivatives - Pharmacokinetics, toxicity and anti-Toxoplasma gondii activity in vivo.
The increasing resistance of Toxoplasma gondii to drugs and side effects of therapy indicate that specific treatment for these parasites is still needed. The 4-arylthiosemicarbazide derivatives seem to be a solution to this challenge because they have low cytotoxicity against host cells and high anti-T. gondii activity. The molecular mechanism for these compounds is related to the inhibition of tyrosine amino acids involved in the proliferation and parasitophorous vacuole formation. The pharmacokinetic analysis shows that 1-(4-Methylimidazol-5-oyl)-4-(4-nitrophenyl)thiosemicarbazide and 4-(3-Iodophenyl)-1-(4-methylimidazol-5-oyl)thiosemicarbazide administered intragastrically pass into the bloodstream and cross the blood-brain barrier, and the absorption of both compounds is first-order absorption. Toxicity analysis shows that our derivatives possess lower toxicity than the routinely used drugs trimethoprim, sulfadiazine and pyrimethamine, as was observed in the level of liver enzymes and creatinine. Both derivatives are highly potent antiparasitic agents against T. gondii, prolonged survival and cure parasite-infected mice. Additionally, significant reductions in cyst formation in the brain and heart were observed, but the highest decreases were noted in muscle and the level of bradyzoites was similar to these observed in mice treated with commercially used drugs. Collectively, the obtained results support the conclusion that both compounds are highly efficacious in a mouse model of acute and chronic toxoplasmosis. Topics: Animals; Antiprotozoal Agents; Mice; Semicarbazides; Toxoplasma; Toxoplasmosis | 2022 |
Systematic Identification of Thiosemicarbazides for Inhibition of
One of the key stages in the development of new therapies in the treatment of toxoplasmosis is the identification of new non-toxic small molecules with high specificity to Topics: Animals; Antiparasitic Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Molecular Structure; Parasitic Sensitivity Tests; Semicarbazides; Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2019 |